Latest Conference Articles

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

September 8th 2021, 6:35pm

Society of Hematologic Oncology Annual Meeting (SOHO)

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

September 8th 2021, 6:11pm

IASLC World Conference on Lung Cancer

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

September 8th 2021, 3:53pm

IASLC World Conference on Lung Cancer

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021, 5:21pm

International Liver Cancer Association Annual Conference

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021, 1:02pm

International Liver Cancer Association Annual Conference

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations

September 5th 2021, 8:27pm

International Liver Cancer Association Annual Conference

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021, 4:34pm

International Liver Cancer Association Annual Conference

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

September 5th 2021, 4:05pm

International Liver Cancer Association Annual Conference

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

High Interferon Signaling and Antigen Presentation Predicts for Response Only in Frontline Advanced HCC

September 5th 2021, 12:04am

International Liver Cancer Association Annual Conference

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021, 4:04pm

International Liver Cancer Association Annual Conference

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021, 4:02pm

International Liver Cancer Association Annual Conference

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Rich on the Prevalence of Cachexia in HCC

September 4th 2021, 4:01pm

International Liver Cancer Association Annual Conference

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

September 4th 2021, 3:55pm

The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.

Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC

September 4th 2021, 3:35pm

International Liver Cancer Association Annual Conference

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

September 3rd 2021, 10:57pm

International Liver Cancer Association Annual Conference

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma

August 16th 2021, 1:13pm

ASCO Direct Highlights

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma

August 13th 2021, 5:35pm

Pan Pacific Lymphoma Conference

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

BTK Inhibitors Represent the Preferred Frontline Regimen in CLL

August 13th 2021, 2:00pm

Pan Pacific Lymphoma Conference

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell Malignancies

August 12th 2021, 7:35pm

Pan Pacific Lymphoma Conference

Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.

Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities

August 12th 2021, 4:00pm

Pan Pacific Lymphoma Conference

As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.